|
|
Companion Study of The Association of Breast Density and Dense Area With Plasma Hormone and Drug Levels in Women With Invasive Breast Cancer Who are Undergoing Adjuvant Aromatase Inhibitor Therapy
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Related Information Registry Information
Alternate Title
Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
No phase specified
|
|
|
|
Biomarker/Laboratory analysis, Diagnostic
|
|
|
|
Closed
|
|
|
|
Postmenopausal
|
|
|
|
NCI
|
|
|
|
NCCTG-N0434 CAN-NCIC-MA27D, N0434 (MA.27D), NCT00316836, MA27D
|
|
|
Special Category:
CTSU trial Objectives Primary - Assess the change in percent breast density and dense area in response to aromatase inhibitor therapy from pretreatment to 1 year, 1 year to 2 years, and pretreatment to 2 years in women with invasive breast cancer.
- Determine the changes in percent breast density and dense area in response to aromatase inhibitor therapy from pretreatment to 1 year and correlate the changes with changes in plasma hormones (e.g., estrone, estrone-sulfate, estradiol, and sex hormone binding globulin) and drug levels (anastrozole or exemestane) over the same period in women with invasive breast cancer.
- Determine the change over time in percent breast density and dense area (from pretreatment to the time period prior to local recurrence) in the contralateral breast in correlation to local recurrence of breast cancer.
Secondary - Determine the change over time in percent breast density and dense area in the contralateral breast in correlation to the development of contralateral breast cancer.
- Determine whether women with high pretreatment percent density (upper tertile) experience greater decreases in percent breast density at 1 and 2 years of aromatase inhibitor therapy than women with low pretreatment percent density (lower tertile).
- Determine whether women with high pretreatment dense area (upper tertile) experience greater decreases in dense area at 1 and 2 years of aromatase inhibitor therapy than women with low pretreatment dense area (lower tertile).
- Correlate haplotype tagged single nucleotide polymorphisms in genes in the aromatase pathway (identified thorough the Mayo Clinic and Indiana University Pharmacogenomics Research Network Projects) with changes in percent and area breast density, plasma hormone levels, and 1-year drug levels.
Entry Criteria Disease Characteristics:
- Histologically confirmed invasive breast cancer
- Completely resected disease
- One intact, noncancerous breast with no prior breast surgery in that breast except breast biopsy
- Mammogram available taken within 12 months prior to enrollment that includes side- and top-down views of the intact, noncancerous breast
- Estrogen receptor- and/or progesterone receptor-positive tumor
Prior/Concurrent Therapy:
- See Disease Characteristics
- More than 6 months since prior hormone replacement therapy, oral contraceptives, tamoxifen, raloxifene, other selective estrogen-receptor modulators, or gonadotropin releasing-hormone analogues before pre-registration mammogram
Patient Characteristics:
- Female
- Postmenopausal
- Agrees to retrieve and digitize mammograms taken prior to registration (within 12 months prior to atudy entry) and at approximately 1 and 2 years post-registration to this study
- Agrees to have an additional blood banking specimen drawn at the same time as pre-treatment specimens are drawn for parent protocol CAN-NCIC-MA27
- Agrees to have blood sample taken at 12 months post-registration on this study
Expected Enrollment 550A total of 550 patients will be accrued for this study. Outcomes Primary Outcome(s)Changes in breast density measured by percent and area at 1 and 2 years Correlation of changes in breast density with plasma hormones and drug levels measured by estrone, estrone-sulfate, estradiol, sex hormone binding globulin, anastrozole, or exemestane levels at 1 and 2 years
Secondary Outcome(s)Correlation of breast density with contralateral breast cancers at 1 and 2 years
Outline This is a multicenter, companion study. Patients complete a 10-minute questionnaire about factors that might affect changes in breast density at baseline and another questionnaire at 1 year and 2 years post registration. Blood samples are collected at baseline (before initiation of treatment ) and at 1 year post registration for hormone and drug level analysis. Mammograms taken prior to registration (within 12 months prior to enrollment) and at approximately 1 and 2 years post-registration to this study are retrieved and digitized for determination of percent breast density and dense area.
Trial Contact Information
Trial Lead Organizations North Central Cancer Treatment Group | | | James Ingle, MD, Protocol chair | | | | Celine Vachon, PhD, Protocol co-chair | | | | Paul Goss, MD, PhD, Protocol co-chair | | Ph: 617-724-3118; 877-726-5130 |
| | Philip Stella, MD, Protocol co-chair | | | | Kathleen Pritchard, MD, Protocol co-chair | | | |
NCIC-Clinical Trials Group | | | Kathleen Pritchard, MD, Protocol chair | | | |
Related Information PDQ® clinical trial CAN-NCIC-MA27 (COMPANION)
Registry Information | | Official Title | | The Association of Breast Density Changes, Plasma Hormone Changes, and Breast Cancer Recurrence: A Companion Study to NCIC CTG MA.27 | | Trial Start Date | | 2006-04-24 | | Trial Completion Date | | 2010-10-30 (estimated) | | Registered in ClinicalTrials.gov | | NCT00316836 | | Date Submitted to PDQ | | 2005-11-22 | | Information Last Verified | | 2008-07-30 | | NCI Grant/Contract Number | | CA25224 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|